Whole genome sequencing

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Research, SAN, DNA, Partnership, Whole genome sequencing, GWAS, Complete Genomics, Genomics, Genome, Antibiotics

The partnership will combine Gencove's platform for data analytics and management with Complete Genomics' sequencing products and automation capabilities via high-throughput nucleic acid extraction, automated library preparation on its DNBSEQ-T7RS* and DNBSEQ-T20X2RS* sequencers.

Key Points: 
  • The partnership will combine Gencove's platform for data analytics and management with Complete Genomics' sequencing products and automation capabilities via high-throughput nucleic acid extraction, automated library preparation on its DNBSEQ-T7RS* and DNBSEQ-T20X2RS* sequencers.
  • "While low-pass whole genome sequencing has long been touted as an advanced method for everything from GWAS analysis to genotyping for molecular breeding, its potential hasn't been fully realized.
  • "Through this partnership with Complete Genomics, we're enabling higher throughput results at a lower cost per sample, making more affordable sequencing accessible to more researchers," said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove.
  • "It will provide the kind of comprehensive genome coverage that leads to the discovery of novel variants."

DNAnexus and Ovation Team Up to Unlock Large-Scale Precision Health Datasets to Accelerate Drug Discovery and Drive Scientific Breakthroughs

Retrieved on: 
Wednesday, January 10, 2024
Data Management, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Software, Genetics, Internet, Telemedicine, Virtual Medicine, Cloud, CLIA, Whole genome sequencing, Patient, Tissue, Privacy, Inflammatory bowel disease, Medicine

DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and Ovation , an omics data company committed to accelerating the development of precision medicine, today announced a collaboration to help streamline large-scale omics data analysis.

Key Points: 
  • DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and Ovation , an omics data company committed to accelerating the development of precision medicine, today announced a collaboration to help streamline large-scale omics data analysis.
  • In the future, the companies plan to extend the collaboration into immunology, oncology, and cardiometabolic therapeutic areas.
  • The secure and scalable DNAnexus Precision Health Data Cloud helps researchers manage, analyze, and collaborate on the complex multimodal data.
  • “Our ability to provide rapid and seamless access to these large cohorts with disease-specific omics data at scale will help deliver richer insights that can accelerate scientific breakthroughs and improve patient care.”

Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing

Retrieved on: 
Tuesday, January 9, 2024
Oncology, Medical Supplies, Health, Health Technology, Genetics, Pharmaceutical, Biotechnology, Senior, Pathology, NGS, SNV, MRD, Patient, Architecture, Collection, DNA, Multimedia, Whole genome sequencing, Cancer, DGX, Lung cancer, Economics, Quest, Genomics, Skin, Hay, Quest Diagnostics, Genome, Ultima, Organization, Machine learning, Breast, Physician, Medical imaging

Ultima recently unveiled its platform technology, a new sequencing architecture that supports sequencing an entire genome for $100.

Key Points: 
  • Ultima recently unveiled its platform technology, a new sequencing architecture that supports sequencing an entire genome for $100.
  • The collaboration will leverage Quest's expertise and scale in oncology, genomics and pathology and national scale in tumor biopsy and blood specimen collection.
  • “Ultima’s technology was designed for applications requiring greater sequencing depth, breadth, or frequency and both MRD testing and whole genome sequencing are premier examples of these.
  • As a result, whole genome sequencing is typically used for rare disease and some oncology testing, but less available for applications targeting large populations.

Baylor Genetics Accelerates Growth, Combines Clinical and Scientific Expertise with Commercial Capabilities to Meet Increased Needs of Patients, Providers and Partners

Retrieved on: 
Wednesday, January 3, 2024
Cancer, Medicine, Treatment, Sequence, Epilepsy, Hospital, Genetics, AI, Calendar, UDN, DSM-IV codes, Texas Medical Center, Bangladesh Technical Education Board, Whole genome sequencing, Genetic testing, Growth, NIH, Patient, WES, Nursing care plan, WGS, Nursing

HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, continued to accelerate its market leadership and growth over the last 12 months, expanding its test menu, commercial reach, lab operations, technology, and customer experience initiatives.

Key Points: 
  • “Baylor Genetics saw strong double-digit growth in the 2023 calendar year, serving a growing roster of top children’s hospitals, leading health systems and partners,” said Kengo Takishima, President and Chief Executive Officer at Baylor Genetics.
  • “With more than 4 million tests performed to date, we are converting scientific innovation into accessible clinical solutions to help transform healthcare and unlock the power of precision medicine.
  • With the analytical expertise of 25 ABMGG-certified clinical lab directors, the lab is designed with multi-omics testing capabilities, scalable automated workflows, advanced robotics, AI, and predictive analytics.
  • Baylor Genetics doubled its commercial team to reach more customers nationwide while adding several new managed care contracts covering an additional 10 million lives.

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Retrieved on: 
Friday, December 1, 2023
Patient, Conference, Hospital, Seizure, Genetic counseling, Whole genome sequencing, Epilepsy, AES, American Epilepsy Society, Diet, National Society, DSM-IV codes, MD, Doctor of Philosophy, Research, Health, NSGC, Parent, Insurance, Test management, Genetic testing, FACMG, Medicaid, Diagnosis, Clinical, WGS, Michelle, GeneDx

The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.

Key Points: 
  • The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
  • Of those patients with a positive genetic diagnosis from exome sequencing, 11% had a variant in a treatment related gene.
  • GeneDx will also present data at the conference that shows insurance may offer better coverage for exome sequencing than multi-gene panels for patients with epilepsy.
  • At the conference, GeneDx will also be hosting an industry sponsored symposium discussing the ways in which exome sequencing can help epilepsy patients find answers sooner.

Precision Medicine Research Report 2023: Diagnostics, Genetic Tests, Esoteric Tests, Therapeutics, Pharmaceuticals, Medical Devices - Global Market to Reach $160 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Health, Pharmaceutical, Diagnosis, Prevalence, Therapy, Whole genome sequencing, Human, Medical device, Human genome, Patient, Medicine, Neurology, Personalized medicine, Cancer, Test management, Growth, NGS, Biomarker, Medication, Government, Big data, Vaccine, Pharmaceutical industry

The "Precision Medicine Market Size, Share & Trends Analysis Report By Application ((Diagnostics (Genetic Tests, Esoteric Tests), Therapeutics (Pharmaceuticals, Medical Devices)), By End Use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Precision Medicine Market Size, Share & Trends Analysis Report By Application ((Diagnostics (Genetic Tests, Esoteric Tests), Therapeutics (Pharmaceuticals, Medical Devices)), By End Use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing.
  • These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses.
  • The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.

PlumCare and Fabric Genomics Announce a Strategic Partnership to Integrate the Fabric AI Platform with PlumCare’s FirstSteps™ Newborn Genome Screening Program in Greece

Retrieved on: 
Thursday, December 7, 2023
Data Management, Biotechnology, Baby, Maternity, Technology, Health, Health Technology, Software, Family, Artificial Intelligence, Genetics, Consumer, Harvard University, Genetic distance, RWE, WGS, Broad Institute, Entrepreneurship, MIT, Whole genome sequencing, Academy of Athens, Multimedia, Patient, Medicine, Textile, Ecosystem, Genomics, Science, Genome, Coronavirus Scientific Advisory Board, MD, Drug discovery, Partnership, Doctor of Philosophy, DSM-IV codes, Antibiotics, Medical device

PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece.

Key Points: 
  • PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece.
  • The goal of FirstSteps , a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.
  • View the full release here: https://www.businesswire.com/news/home/20231207013080/en/
    The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece.
  • Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program.

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on: 
Friday, November 17, 2023
Science, Biotechnology, Research, Oncology, Health, Data Management, Technology, Genetics, TMB, GCN, Multimedia, Whole genome sequencing, Personalized medicine, Conference, Treatment of lung cancer, Diagnosis, MET, Insight, NGS, Biomarker, Poster, AACR, NSCLC, Antibiotics, Cancer, Hong Kong

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points: 
  • Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
  • (Photo: Business Wire)
    Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
  • Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
  • "We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.

Breast Cancer Multiomics: Unified Insights in Tumor Heterogeneity, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, December 12, 2023
WGS, PST, ASCP, Whole genome sequencing, IDT, Gold, Disease, Breast cancer, Informatics, Transcriptome, Patient, CNV, Ductal carcinoma, MB, EST, Doctor of Philosophy, RNA-Seq, BioLegend, Cell, Vaccine

TORONTO, Dec. 12, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar exploring a novel single-cell method for breast cancer multiomics, linking genetic variations, copy number changes and gene expressions with focused panels. While the information obtained from whole genome sequencing (WGS) studies is a clear gold standard for discovery-based sequencing, current sequencing costs and informatics challenges frequently diminish WGS usage. Instead, applications focus on exonic spaces, particularly druggable targets. The majority of these are small, focused panels — resulting in a significant resolution gap between comprehensive WGS and these focal panels.

Key Points: 
  • In this free webinar, explore a new method detailing genetic insights into breast cancer, enabling precise assessment of variations, gene expressions and targeted proteins at a single-cell level.
  • TORONTO, Dec. 12, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar exploring a novel single-cell method for breast cancer multiomics, linking genetic variations, copy number changes and gene expressions with focused panels.
  • In this webinar, the featured speaker describes the utility of the IDT v2 exome hybrid capture after ResolveOME single-cell workflow in a cohort of cells derived from breast cancer patients.
  • Join this webinar to explore a new method detailing genetic insights into breast cancer, enabling precise assessment of variations, gene expressions and targeted proteins at a single-cell level.

Genpax named 2023 winners of the IET Excellence and Innovation Award for Health Technology

Retrieved on: 
Wednesday, November 29, 2023
WGS, Engineering, Whole genome sequencing, IET, Science, Glasgow Science Centre, The Economist, IPC, Control, Excellence, Infection, AME Publishing Company, Public, Pharmaceutical industry, Health care

LONDON, Nov. 29, 2023 /PRNewswire/ -- Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial pathogens, has been announced as a winner by the IET for their 2023 Excellence and Innovation Awards.

Key Points: 
  • LONDON, Nov. 29, 2023 /PRNewswire/ -- Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial pathogens, has been announced as a winner by the IET for their 2023 Excellence and Innovation Awards.
  • The Awards celebrate the most pioneering engineering and technology innovations across 16 sectors, from energy and sustainability to manufacturing and healthcare.
  • Chosen by a panel of expert judges, Genpax won the Health Technology award for their revolutionary pathogen analysis platform IDEM.
  • Dr Nigel Saunders, Chief Scientific Officer and co-founder, said, "I am delighted that IDEM has been recognised for its innovation.